Results 21 to 30 of about 5,090 (179)

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec [PDF]

JAAD Case Reports
Matthew M. Wallace, MD, John A. Zitelli, MD   +1 more
doaj   +2 more sources

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec [PDF]

JAAD Case Reports, 2023
Neha Singh, BS, Erin McClure, BS, Coley Doolittle-Amieva, PA-C, Upendra Parvathaneni, MD, Shailender Bhatia, MD, Ata S. Moshiri, MD, MPH   +5 more
doaj   +2 more sources

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. [PDF]

Cancer Sci, 2022
Yamazaki N, Isei T, Kiyohara Y, Koga H, Kojima T, Takenouchi T, Yokota K, Namikawa K, Yi M, Keegan A, Fukushima S.   +10 more
europepmc   +2 more sources

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial [PDF]

, 2016
Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate ...
Kevin Harrington, Robert Andtbacka, Frances Collichio, Gerald Downey, Lisa Chen, Zsolt Szabo, Howard Kaufman   +6 more
core   +9 more sources

Vaccinating against cancer: getting to prime time

Journal for ImmunoTherapy of Cancer, 2023
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize.
Lawrence Fong, Ryan Chang
doaj   +1 more source

Talimogene laherparepvec induced bullous pemphigoid. [PDF]

JAAD Case Rep
Davoudi S, Mahmoud F, Abbott J.
europepmc   +2 more sources

Commentary on oncolytic viruses: past, present, and future

Journal for ImmunoTherapy of Cancer, 2023
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as ...
Christopher Larson, Bryan Oronsky, Tony R Reid   +2 more
doaj   +1 more source

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. [PDF]

Cancers (Basel), 2021
Ferrucci PF, Pala L, Conforti F, Cocorocchio E.   +3 more
europepmc   +2 more sources

Immunotherapy, Inflammation and Colorectal Cancer. [PDF]

, 2020
Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States.
Karin, Michael, Lichtenstern, Charles Robert, Ngu, Rachael Katie, Shalapour, Shabnam   +3 more
core   +1 more source

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC) [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Talimogene laherparepvec (T-VEC) is an intralesional oncolytic viral therapy for the treatment of recurrent, unresectable cutaneous, subcutaneous, and nodal melanoma.
Jennifer Gardner, Teresa Hyun, Gideon Steinbach, John Thompson   +3 more
doaj   +1 more source